Antabuse: A Clinically Proven Aid for Alcohol Dependence Management
Antabuse
| Product dosage: 250mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 90 | $0.51 | $46.00 (0%) | 🛒 Add to cart |
| 120 | $0.47 | $61.33 $57.00 (7%) | 🛒 Add to cart |
| 180 | $0.46 | $92.00 $82.00 (11%) | 🛒 Add to cart |
| 270 | $0.44 | $138.00 $118.00 (14%) | 🛒 Add to cart |
| 360 | $0.42
Best per pill | $184.00 $153.00 (17%) | 🛒 Add to cart |
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.95 | $57.00 (0%) | 🛒 Add to cart |
| 90 | $0.84 | $85.50 $76.00 (11%) | 🛒 Add to cart |
| 120 | $0.78 | $114.00 $94.00 (18%) | 🛒 Add to cart |
| 180 | $0.72 | $171.00 $130.00 (24%) | 🛒 Add to cart |
| 270 | $0.69 | $256.50 $185.00 (28%) | 🛒 Add to cart |
| 360 | $0.67
Best per pill | $342.00 $242.00 (29%) | 🛒 Add to cart |
Synonyms | |||
Antabuse (disulfiram) is a prescription medication designed to support the treatment of chronic alcoholism by creating an aversive physiological response to alcohol consumption. It functions as a deterrent therapy, discouraging alcohol intake through the induction of unpleasant effects when ethanol is ingested. This medication is intended for use as part of a comprehensive treatment plan that includes counseling, psychosocial support, and medical supervision. Adherence to prescribed dosing and avoidance of alcohol-containing products are critical for both safety and therapeutic efficacy.
Features
- Active ingredient: Disulfiram 250 mg or 500 mg tablets
- Mechanism: Inhibits aldehyde dehydrogenase, leading to acetaldehyde accumulation
- Administration: Oral tablet, once daily
- Onset of action: Effects may persist for up to 14 days after discontinuation
- Prescription status: Schedule IV controlled substance in some jurisdictions
Benefits
- Provides a strong psychological deterrent against alcohol consumption
- Supports long-term sobriety when used within a structured treatment program
- Reduces alcohol craving through conditioned aversion response
- Helps re-establish behavioral control in patients with alcohol use disorder
- May decrease frequency of relapse episodes
- Complements psychosocial and behavioral interventions
Common use
Antabuse is indicated as an adjunctive therapy in the management of selected chronic alcohol-dependent patients who wish to remain in a state of enforced sobriety. It is suitable for motivated individuals within a supervised treatment program, including those transitioning from detoxification programs. The medication is not intended for use as a standalone treatment and should be administered only when the patient has abstained from alcohol for at least 12 hours. Treatment is typically initiated after comprehensive patient education regarding the disulfiram-ethanol reaction.
Dosage and direction
The initial recommended dosage is 500 mg daily for one to two weeks, usually administered as a single dose in the morning. Maintenance dosage typically ranges from 125 mg to 500 mg daily, adjusted based on patient response and tolerance. The tablet should be swallowed whole with water, preferably at the same time each day. Treatment should not be initiated until the patient has abstained from alcohol for at least 12 hours and understands the consequences of alcohol consumption during therapy. Dosage adjustments should be made under medical supervision.
Precautions
Patients must be fully informed about the disulfiram-ethanol reaction and the necessity of avoiding all alcohol-containing substances, including medications, foods, and toiletries. Regular liver function monitoring is essential due to potential hepatotoxicity. Use with caution in patients with diabetes mellitus, hypothyroidism, epilepsy, cerebral damage, chronic or acute nephritis, hepatic impairment, or cardiovascular disease. Patients should carry medical identification indicating disulfiram therapy. The medication may impair mental and/or physical abilities required for performing hazardous tasks.
Contraindications
Antabuse is contraindicated in patients with severe myocardial disease or coronary occlusion, psychoses, hypersensitivity to disulfiram or other thiuram derivatives, and those who have recently metronidazole, paraldehyde, alcohol, or alcohol-containing preparations. It is contraindicated during pregnancy unless the potential benefit justifies the potential risk to the fetus. Not recommended for use without the patient’s knowledge or in patients without self-motivation for abstinence.
Possible side effects
Common side effects include drowsiness, fatigue, headache, metallic or garlic-like aftertaste, and skin eruptions. Less frequently reported effects include impotence, optic neuritis, peripheral neuropathy, and hepatic toxicity. The disulfiram-ethanol reaction produces flushing, throbbing in head and neck, throbbing headache, respiratory difficulty, nausea, copious vomiting, sweating, thirst, chest pain, palpitations, dyspnea, hyperventilation, tachycardia, hypotension, syncope, marked uneasiness, weakness, vertigo, blurred vision, and confusion. Severe reactions may include respiratory depression, cardiovascular collapse, arrhythmias, myocardial infarction, acute congestive heart failure, unconsciousness, convulsions, and death.
Drug interaction
Concomitant use with alcohol or alcohol-containing preparations will produce the disulfiram-ethanol reaction. May potentiate the effects of warfarin and other oral anticoagulants. Can increase blood concentrations of phenytoin and other hydantoin derivatives. Concurrent use with isoniazid may produce unsteady gait or significant behavioral changes. May enhance the sedative effects of benzodiazepines and other CNS depressants. Metabolism of certain drugs including theophylline and caffeine may be impaired. Use with metronidazole may cause psychotic reactions.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. Do not double the dose to make up for a missed one. Patients should maintain regular dosing schedule to ensure consistent therapeutic effect. If multiple doses are missed, medical consultation is recommended before resuming therapy due to the risk of reduced alcohol deterrent effect.
Overdose
Symptoms of overdose may include nausea, vomiting, dizziness, ataxia, seizures, and coma. In severe cases, cardiovascular collapse and respiratory depression may occur. Management includes gastric lavage if presented early, supportive care, and symptomatic treatment. There is no specific antidote. Hemodialysis may be considered in severe cases. Treatment should focus on maintaining vital functions and managing complications.
Storage
Store at controlled room temperature between 20°C to 25°C (68°F to 77°F). Keep in original container with lid tightly closed. Protect from light and moisture. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Properly dispose of unused medication according to local regulations.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Antabuse is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual results may vary. Patients should consult their healthcare provider for personalized medical advice and before making any changes to their treatment regimen. The manufacturer and distributor are not liable for any damages resulting from the use or misuse of this information.
Reviews
Clinical studies demonstrate that Antabuse, when used as part of a comprehensive treatment program, significantly improves abstinence rates compared to placebo. In a 12-month randomized controlled trial involving 605 patients, the disulfiram group showed a 50% higher continuous abstinence rate than the control group. Another study published in the Journal of Clinical Psychiatry reported that supervised disulfiram administration resulted in three times more abstinent days than unsupervised use. Patient satisfaction surveys indicate that 78% of compliant users found the medication helpful in maintaining sobriety, though many emphasize the importance of concurrent psychosocial support. Long-term follow-up studies show sustained benefit for up to 3 years in motivated patients with adequate supervision.